MK-1084 Clinical Trials (2026): 3 Studies for Advanced Solid Tumors & Lung Neoplasm Malignant
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 MK-1084 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Advanced Solid Tumors & Lung Neoplasm Malignant) and 498 total planned enrollment. 3 MK-1084 clinical trials are actively recruiting at 11 U.S. sites across 7 states. Most recent activity: NCT07252739 (Jan 2033).
Where to Participate: All MK-1084 Trial Sites in the U.S. (11 sites across 7 states)
Every actively recruiting MK-1084trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Clermont Oncology Center ( Site 0041) | Clermont34711 | NCT07252739 | Map |
| FL | Clermont Oncology Center ( Site 0041) | Clermont34711 | NCT07286149 | Map |
| IL | Northwestern Memorial Hospital ( Site 0002) | Chicago60611 | NCT05853367 | Map |
| IL | University of Illinois Hospital & Health Sciences System ( Site 0044) | Chicago60612 | NCT07286149 | Map |
| KY | The University of Louisville, James Graham Brown Cancer Center ( Site 0004) | Louisville40202 | NCT05853367 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) | Hackensack07601 | NCT05853367 | Map |
| NJ | Rutgers Cancer Institute of New Jersey ( Site 0005) | New Brunswick08901 | NCT05853367 | Map |
| ND | Sanford Health Roger Maris Cancer Center ( Site 0039) | Fargo58102 | NCT07252739 | Map |
| OR | Providence Oncology and Hematology Care Clinic - Westside ( Site 0059) | Portland97225 | NCT07286149 | Map |
| OR | Providence Portland Medical Center ( Site 0043) | Portland97213 | NCT07286149 | Map |
| SD | Sanford Cancer Center Oncology Clinic ( Site 0038) | Sioux Falls57104 | NCT07252739 | Map |
MK-1084 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
| P1/P2 | 1 | 1 |
| P2 | 1 | 1 |
Recruiting MK-1084 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07252739 | NSCLCKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | P2 | Malignant Neoplasm | 130 | Dec 2025 |
| NCT07286149 | MK-3475-01FA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | P1/P2 | Lung Neoplasm Malignant | 190 | Apr 2026 |
| NCT05853367 | MK-0472-001Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | P1 | Metastatic Solid Tumors | 178 | Jul 2023 |
MK-1084 clinical trials by indication
Lung Neoplasm Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07286149 | MK-3475-01F | P1/P2 | recruiting | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) |
Malignant Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07252739 | NSCLC | P2 | recruiting | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) |
Metastatic Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05853367 | MK-0472-001 | P1 | recruiting | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) |
MK-1084 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| NSCLC | NCT07252739 | P2 | recruiting | Malignant Neoplasm | 130 | — |
All MK-1084 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07252739 | NSCLC | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | P2 | recruiting | 130 | Merck Sharp & Dohme LLC | Dec 2025 |
| NCT07286149 | MK-3475-01F | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | P1/P2 | recruiting | 190 | Merck Sharp & Dohme LLC | Apr 2026 |
| NCT05853367 | MK-0472-001 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | P1 | recruiting | 178 | Merck Sharp & Dohme LLC | Jul 2023 |
MK-1084 clinical trials: frequently asked questions
- How many MK-1084 clinical trials are there?
- 3 MK-1084 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are MK-1084 clinical trials recruiting in 2026?
- Yes — 3 MK-1084 trials are actively recruiting in 2026, with 11 U.S. sites across 7 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is MK-1084 being studied for?
- MK-1084 is being studied for Advanced Solid Tumors, Lung Neoplasm Malignant, Malignant Neoplasm, Metastatic Solid Tumors. The trials are grouped by indication on this page.
- What phase is MK-1084 in?
- MK-1084 clinical trials span 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors MK-1084 clinical trials?
- The lead sponsor across the most MK-1084 trials is Merck Sharp & Dohme LLC. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming MK-1084as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: